Clinical Research Directory

Inclusion Criteria: * Patients with HCC for whom TARE decision was made at the MDT * Patients ≥ 18 years of age * Diagnosis of HCC based on imaging (EASL guidelines) and confirmed histologically * At least one target lesion to be treated by radioembolisation, naïve to any previous treatment * Child-Pugh Class \< B8 * Eastern Cooperative Oncology Group (ECOG) ≤ 2 * Life expectancy ≥ 3 months * Available baseline imaging (multiphasic CT), performed within 6 weeks before the beginning of TARE Exclusion Criteria: * Patient with contraindication to MRI * Patient with contraindication to 18F-choline : potential hypersensitivity to the product or to any excipients * Non-adequate bone marrow, liver and renal function within 15 days prior to work-up as assessed by the following laboratory tests: * Hemoglobin ≤ 8.0 g/Dl * Platelet count \< 50,000/ mm3 * Total bilirubin \> 3 mg/dL (or \> 51 µmol/ L). * Prothrombin time ≤ 50% * Glomerular Filtration Rate (GFR) \< 35 mL/min/1.73 m2 * Infiltrating tumor more than 70% of the liver * Prior liver transplantation * Initial prescription for SIRT and concomitant systemic treatment * Patient refusal to give written and informed consent * No affiliation to a social security regimen or CMU * Patient under State Medical Aid * Known pregnancy or breastfeeding women * Patient deprived of freedom, subject under a legal protective measure * Any significant medical, psychiatric, or surgical condition that is uncontrolled and could endanger the subject's safety or limit adherence to the study's objectives and assessments